The White House’s efforts to combat high drug prices are falling short, according to a report released ahead of a planned appearance by the Trump administration’s top health official.
Democrats on the Senate Finance Committee released a report Tuesday outlining the drivers of high drug costs and how the Trump administration’s blueprint to combat the problem is inadequate. Health and Human Services Secretary Alex Azar is expected to testify before the committee about drug prices Tuesday.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.